Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance

BACKGROUND: Alectinib has shown a greater efficacy to ALK-rearranged non-small-cell lung cancers in first-line setting; however, most patients relapse due to acquired resistance, such as secondary mutations in ALK including I1171N and G1202R. Although ceritinib or lorlatinib was shown to be effectiv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EBioMedicine
Main Authors: Okada, Koutaroh, Araki, Mitsugu, Sakashita, Takuya, Ma, Biao, Kanada, Ryo, Yanagitani, Noriko, Horiike, Atsushi, Koike, Sumie, Oh-hara, Tomoko, Watanabe, Kana, Tamai, Keiichi, Maemondo, Makoto, Nishio, Makoto, Ishikawa, Takeshi, Okuno, Yasushi, Fujita, Naoya, Katayama, Ryohei
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2019
Assuntos:
Research paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6441848/
https://ncbi.nlm.nih.gov/pubmed/30662002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.01.019
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados